Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Oral Etoposide in Metastatic HER2 Negative Breast Cancer
NCT03535961Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in breast cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 1 year. Started May 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03535961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535961.